The Charles T. Campbell Eye Microbiology Lab
UPMCUniversity of Pittsburgh Schools of the Health Sciences
HomeContact InformationLab Diagnostic TestingAntibiotic SusceptibilityAntimicrobial TherapyCurrent ResearchPhotos

Ocular Microbiology and Immunology Group
Back to OMIG Main Page

2015 Agenda and Abstracts | < Previous | Next >

2015 OMIG Abstract 27

Low-dose topical preservative-free Dexamethasone 0.01% and 0.05% for treatment of chronic ocular surface disease unresponsive to commercially available steroids, antibiotics, and anti-allergy agents
A. Mallick, F. Chin, C. Shih, I. Udell, A. Steiner

Purpose: To evaluate the short-term safety and efficacy of topical preservative-free dexamethasone 0.01% and 0.05% for the treatment of ocular surface disease and/or tearing refractory to conventional treatments.  Patients’ diagnoses included dry eye syndrome, blepharitis, rosacea, meibomian gland dysfunction, graft versus host disease, Sjogren’s Syndrome, Steven-Johnson Syndrome, allergic conjunctivitis, superior limbic keratoconjunctivitis, and limbal stem cell deficiency.
Methods: Retrospective chart review of patients who received topical preservative-free dexamethasone 0.01% and 0.05% (Leiter’s Pharmacy, San Jose, CA) from 9/2011 to 1/2015. Follow-up visits were reviewed for subjective responses to the formulation, development of visually significant cataract, and intraocular pressure (IOP). Responses were graded as moderate/complete resolution of symptoms (50%–100% improvement), mild improvement (25%–50% improvement), or no improvement.
Results: One-hundred-twenty-two eyes of sixty-one patients received topical preservative-free dexamethasone for the treatment of ocular surface disease. Of these patients, 55 received 0.01% and 6 patients received 0.05% formulations.  Follow up ranged from 1 to 49 months. Forty-four patients (72%) reported moderate or complete resolution of ocular symptoms. Eleven patients (18%) had mild improvement in their symptoms. Six patients (10%) had no change in ocular symptoms.
Three patients in our series developed an elevation of intraocular pressure greater than 5 mm Hg above baseline intraocular pressure. Of these patients, two were initially given 0.05% with subsequent reduction of IOP when switched to 0.01%.  One patient developed IOP elevation on 0.01%, however had a history of end stage glaucoma.   One patient in our series developed progression of cataract requiring surgery. 
Of the twenty-nine patients previously treated with commercially available steroids (with preservative), twenty-two patients (76%) reported moderate or complete resolution of symptoms, six patients mild improvement (21%), and one patient (3%) reported no improvement with use of topical preservative-free dexamethasone.
Conclusions: Topical preservative-free dexamethasone 0.01% and 0.05% could be an effective therapy for recalcitrant chronic ocular surface disease.  Minimal risk exists of IOP elevation or formation of visually significant cataract.
Disclosure: N

2015 Agenda and Abstracts | < Previous | Next >